New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
06:11 EDTOGXIOncoGenex reports target number of events reached in Phase 3 SYNERGY trial
OncoGenex Pharmaceuticals announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer. Overall survival results will remain blinded until all study data have been thoroughly reviewed and prepared for final analysis. Custirsen received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel/prednisone. The FDA also agreed on the design of the SYNERGY trial via the Special Protocol Assessment process.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
07:10 EDTOGXIOncoGenex receives EMA support for Phase 3 prostate cancer trial amendment
Subscribe for More Information
September 30, 2015
07:05 EDTOGXIOncoGenex completes patient enrollment in clinical trial for bladder cancer
Subscribe for More Information
September 28, 2015
05:16 EDTOGXIOncoGenex announces results from Phase 3 trial of custirsen treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use